| scholarly article | Q13442814 |
| P50 | author | Steven E. Wilson | Q57068193 |
| P2093 | author name string | Rodrigo Carlos de Oliveira | |
| P2860 | cites work | The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome. | Q50480678 |
| The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy. | Q50524947 | ||
| Sjogren's syndrome from the perspective of ophthalmology. | Q50887089 | ||
| Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. | Q52608828 | ||
| Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal. | Q53143850 | ||
| Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. | Q53620228 | ||
| Topical Cyclosporine Pretreatment of Ocular Surface in Allogeneic Hematopoietic Stem Cell Transplant Recipients | Q56983060 | ||
| Comparison of Ocular Surface Mucin Expression After Topical Ophthalmic Drug Administration in Dry Eye-Induced Mouse Model | Q57458475 | ||
| A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease | Q57484944 | ||
| Effects of Sequential Artificial Tear and Cyclosporine Emulsion Therapy on Conjunctival Goblet Cell Density and Transforming Growth Factor-β2 Production | Q61851319 | ||
| Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection | Q70195676 | ||
| Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes | Q73180482 | ||
| Inflammation: a unifying theory for the origin of dry eye syndrome | Q75260274 | ||
| The pathology of dry eye: the interaction between the ocular surface and lacrimal glands | Q77575256 | ||
| Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine | Q77729873 | ||
| The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) | Q80347907 | ||
| The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007) | Q80347909 | ||
| Uses and safety profile of ciclosporin in ophthalmology | Q80435644 | ||
| [Topical cyclosporine A and risk of ocular surface neoplasia] | Q87692288 | ||
| Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease | Q90931447 | ||
| Molecular evidence for the role of inflammation in dry eye disease | Q90985706 | ||
| Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System | Q91354085 | ||
| Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review | Q26770830 | ||
| Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis | Q28572316 | ||
| Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model | Q32061871 | ||
| The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca | Q33218520 | ||
| Iatrogenic glaucoma secondary to medications | Q33752399 | ||
| High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen | Q34076208 | ||
| Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years | Q34443357 | ||
| What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. | Q34600337 | ||
| Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis | Q35166231 | ||
| Aqueous Tear Deficiency Increases Conjunctival Interferon-γ (IFN-γ) Expression and Goblet Cell Loss | Q36345503 | ||
| Interferon-γ-Induced Unfolded Protein Response in Conjunctival Goblet Cells as a Cause of Mucin Deficiency in Sjögren Syndrome | Q36990222 | ||
| Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting | Q38151227 | ||
| Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis | Q38516740 | ||
| TFOS DEWS II pathophysiology report | Q38652987 | ||
| TFOS DEWS II Epidemiology Report | Q38652994 | ||
| TFOS DEWS II Definition and Classification Report. | Q38665717 | ||
| Modern approaches to the ocular delivery of cyclosporine A. | Q38808718 | ||
| Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts | Q39185845 | ||
| Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. | Q39203016 | ||
| Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye. | Q39298994 | ||
| TFOS DEWS II Management and Therapy Report | Q39453364 | ||
| Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group | Q40765221 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| Evaluation of topical cyclosporine for the treatment of dry eye disease | Q44443222 | ||
| Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease | Q44961509 | ||
| Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease | Q47645371 | ||
| The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research | Q47884949 | ||
| Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. | Q48648762 | ||
| Frequent Dosing of Topical Cyclosporine A for Severe Ocular Surface Disease. | Q50234807 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | cyclosporine | Q367700 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 1115-1122 | |
| P577 | publication date | 2019-07-01 | |
| P1433 | published in | Clinical Ophthalmology | Q5133782 |
| P1476 | title | Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease | |
| P478 | volume | 13 |
| Q94553034 | Anti-inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye | cites work | P2860 |
Search more.